IL129910A0 - Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis - Google Patents

Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis

Info

Publication number
IL129910A0
IL129910A0 IL12991097A IL12991097A IL129910A0 IL 129910 A0 IL129910 A0 IL 129910A0 IL 12991097 A IL12991097 A IL 12991097A IL 12991097 A IL12991097 A IL 12991097A IL 129910 A0 IL129910 A0 IL 129910A0
Authority
IL
Israel
Prior art keywords
low density
methods
density lipoprotein
binding proteins
treating atherosclerosis
Prior art date
Application number
IL12991097A
Other languages
English (en)
Original Assignee
Boston Heart Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Heart Foundation Inc filed Critical Boston Heart Foundation Inc
Publication of IL129910A0 publication Critical patent/IL129910A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
IL12991097A 1996-11-27 1997-11-26 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis IL129910A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3193096P 1996-11-27 1996-11-27
US4854797P 1997-06-03 1997-06-03
PCT/US1997/021857 WO1998023282A1 (en) 1996-11-27 1997-11-26 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis

Publications (1)

Publication Number Publication Date
IL129910A0 true IL129910A0 (en) 2000-02-29

Family

ID=26707786

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12991097A IL129910A0 (en) 1996-11-27 1997-11-26 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis

Country Status (10)

Country Link
US (2) US6355451B1 (de)
EP (1) EP0969855B1 (de)
JP (1) JP4184437B2 (de)
AT (1) ATE317264T1 (de)
AU (1) AU736142B2 (de)
CA (1) CA2272243A1 (de)
DE (1) DE69735243T2 (de)
ES (1) ES2258798T3 (de)
IL (1) IL129910A0 (de)
WO (1) WO1998023282A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632923B1 (en) * 1996-11-27 2003-10-14 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
US6605588B1 (en) 1996-11-27 2003-08-12 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
WO2002102250A1 (en) * 1999-10-22 2002-12-27 Glaxo Group Limited $g(in vivo) imaging
CN1329142A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——rna聚合酶ii相关蛋白11.33和编码这种多肽的多核苷酸
US20050154407A1 (en) * 2000-12-20 2005-07-14 Fox Hollow Technologies, Inc. Method of evaluating drug efficacy for treating atherosclerosis
US20060032508A1 (en) * 2000-12-20 2006-02-16 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
EP3434276B1 (de) 2012-06-06 2024-10-30 Pepkon Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von krebs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59206046A (ja) * 1983-05-11 1984-11-21 Asahi Chem Ind Co Ltd 低比重リポ蛋白質を吸着する材料
US4660563A (en) 1984-12-31 1987-04-28 Massachusetts Institute Of Technology Method and means for detection of arterial lesions
US4877599A (en) 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5726153A (en) 1988-05-02 1998-03-10 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5135848A (en) 1989-10-23 1992-08-04 Lehigh University And Northeast Benjamin Franklin Technology Center Of Pa Methods for evaluating cholesterol metabolism and reagents therefor
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
JPH05507276A (ja) 1990-05-03 1993-10-21 ニュー・イングランド・ディーコネス・ホスピタル・コーポレイション 動脈造影用合成ペプチド類
DE4222385A1 (de) 1992-07-08 1994-01-13 Boehringer Ingelheim Int Verfahren zur Isolierung von Inhibitoren des Rhinovirus-Rezeptors
EP0586094A1 (de) 1992-08-03 1994-03-09 Wisconsin Alumni Research Foundation Löslicher LDL-Rezeptor und Gen
AU6234194A (en) 1993-01-15 1994-08-15 Board Of Regents, The University Of Texas System High molecular weight b-cell growth factor: interleukin-14
JPH09163988A (ja) 1995-10-09 1997-06-24 Kowa Co 新規なｌｄｌ受容体類似蛋白質及び遺伝子

Also Published As

Publication number Publication date
DE69735243D1 (de) 2006-04-20
WO1998023282A1 (en) 1998-06-04
EP0969855B1 (de) 2006-02-08
US20020052033A1 (en) 2002-05-02
AU736142B2 (en) 2001-07-26
JP2001506983A (ja) 2001-05-29
JP4184437B2 (ja) 2008-11-19
DE69735243T2 (de) 2006-11-02
ATE317264T1 (de) 2006-02-15
AU7408898A (en) 1998-06-22
ES2258798T3 (es) 2006-09-01
US6355451B1 (en) 2002-03-12
CA2272243A1 (en) 1998-06-04
EP0969855A4 (de) 2001-08-16
EP0969855A1 (de) 2000-01-12

Similar Documents

Publication Publication Date Title
Wilkinson Troponin C from rabbit slow skeletal and cardiac muscle is the product of a single gene
AU2001243322A1 (en) Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
NZ332634A (en) Isolated autophosphorylating polypeptide having phosphoinositide-3-kinase activity
EP1637608A3 (de) Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
BR9712518A (pt) Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico
Appelbaum et al. In vivo phosphorylation of the lamin B receptor. Binding of lamin B to its nuclear membrane receptor is affected by phosphorylation.
TR199802082T2 (xx) Otoantigen ve otoim�n hastal�klar�n im�noterapisinde kullan�lmak i�in otoantigen yap�sal olarak ili�kili proteinler.
IL129910A0 (en) Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
BR9506377A (pt) Peptídeo compreendendo uma subsequéncia de gp-39 hc proteina gp-39 hc ou peptideos composição farmacéutica uso da proteina gp-39 hc ou um ou mais dos peptídeos composição de diagnostico e processo de diagnóstico e kit de teste para a detecção de céçiças t auto-reativas ativadas
ES2173471T3 (es) Analisis para homocisteina y homocisteina desulfurasa a partir de tricomonas viginalis de protozoos.
DK525384D0 (da) Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
NO972063L (no) Isolert BMP-reseptorkinaseprotein, DNA-sekvens, rekombinant ekspresjonsvektor samt vertscelle
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
EP0300487A3 (en) Enzymatically inactive, immunologically active beta-galactosidase muteins
EP2301947A3 (de) Sekretierte Proteine und Verwendungen dafür
WO1999020761A3 (en) Compositions and methods for identifying and testing therapeutics against hsv infection
Eyre et al. Experimentally induced osteoarthrosis in the dog
Scott et al. Production of fibrolast-pneumocyte-like factor by fetal rabbit lung fibroblasts: Isolation and effects of it and related factors on fetal type II cells in vitro
Seidah et al. Isolation and partial characterization of a biosynthetic N-terminal methionyl peptide of bovine pars intermedia: Relationship to ubiquitin
Takatsuki et al. Extraction, purification, and partial characterization of bovine parathyroid secretory protein.
Liu et al. Rapid catabolism of tyrosine-O-sulphated proteins and the formation of free tyrosine O-sulphate as an end product in rat embryo fibroblasts
McCormick et al. Serum proteins as carriers of amino acids to and from the hindlimbs of fed and fasted calves